Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
NCT07831369Phase 2Recruiting
- Sponsor
- Inova Health System
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of valproic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and simvastatin in glioblastoma (GBM) and glioma (2 arms), sponsored by Inova Health System. Primary endpoint: Objective Response Rate at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
valproic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabsimvastatin
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT07831369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831369.